BJU Int
- SIGHINOLFI MC, Pallotta G, Assumma S, Panio E, et al 
 A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: 
study protocol with FPG500 to detect actionable alterations representative of 
progressive disease.
 BJU Int. 2025 Oct 10. doi: 10.1111/bju.70019.
 
 
- MARQUIS A, Schwartz MJ, Armache A, Solosky K, et al 
 Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate 
cancer: medium-term outcomes and learning curve insights.
 BJU Int. 2025 Oct 9. doi: 10.1111/bju.70014.
 
 
- GILL S, Chen R, Lamb BW, Moore CM, et al 
 Interventions for patients with prostate cancer on active surveillance: a 
narrative review.
 BJU Int. 2025 Oct 6. doi: 10.1111/bju.70005.
 
 
 BMC Cancer
 
 
- GHOLIZADE M, Yazdani E, Hosseini-Baharanchi FS, Nikoofar A, et al 
 Variations in radiomic features of the femoral head and neck during helical 
tomotherapy in prostate and rectal cancer patients.
 BMC Cancer. 2025;25:1509.
 
 
 BMJ Oncol
 
 
- STEWART KT, Choudhury A 
 Understanding prostate cancer care: recent progress and future direction.
 BMJ Oncol. 2025;4:e000985.
 
 
 Br J Cancer
 
 
- NIKHIL K, Haymour HS, Kamra M, Shah K, et al 
 Correction: Phosphorylation-dependent regulation of SPOP by LIMK2 promotes 
castration-resistant prostate cancer.
 Br J Cancer. 2025 Oct 9. doi: 10.1038/s41416-025-03212.
 
 
 Cancer
 
 
- TSUNG I, Reichert ZR, Ramalingam SS 
 Reply to "From treatment escalation to ultra de-intensification: When 
androgen-deprivation therapy alone remains a rational choice in metastatic 
hormone-sensitive prostate cancer".
 Cancer. 2025;131:e70119.
 
 
- ROVIELLO G, Catalano M, Antonuzzo L 
 From treatment escalation to ultra de-intensification: When androgen-deprivation 
therapy alone remains a rational choice in metastatic hormone-sensitive prostate 
cancer.
 Cancer. 2025;131:e70117.
 
 
 Eur Urol
 
 
- WANG Z, Li X, Zhao X, Yang Y, et al 
 Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. 
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate 
Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In 
press. https:/
 Eur Urol. 2025 Oct 9:S0302-2838(25)04728-1. doi: 10.1016/j.eururo.2025.
 
 
- IORI F, Ali E, Iotti C 
 Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen 
Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk 
Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. 
Eur Urol. In pre
 Eur Urol. 2025 Oct 9:S0302-2838(25)04726-8. doi: 10.1016/j.eururo.2025.09.4167.
 
 
- MENG X, Hua Y, Song R 
 Re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of 
Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent 
Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK 
Study. Eur Urol 20
 Eur Urol. 2025 Oct 9:S0302-2838(25)04727-X. doi: 10.1016/j.eururo.2025.
 
 
- ENGLMAN C, Giganti F, Moore CM 
 Reply to Francesco Montorsi, Paolo Zauirto, and Giorgio Gandaglia's Letter to the 
Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic 
Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: 
Updated Results
 Eur Urol. 2025 Oct 7:S0302-2838(25)04703-7. doi: 10.1016/j.eururo.2025.09.4153.
 
 
- KHALIL N, Maiolino G, Barret E 
 Re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal 
Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging 
Perspectives. Eur Urol 2025;88:123-5.
 Eur Urol. 2025 Oct 6:S0302-2838(25)04709-8. doi: 10.1016/j.eururo.2025.09.4159.
 
 
- HOLMBERG L, Adami HO, Bill-Axelson A 
 Reply to Yafei Wang, Qianting Lu, and Xin Zhao's Letter to the Editor re: Lars 
Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in 
the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting 
in Early P
 Eur Urol. 2025 Oct 6:S0302-2838(25)04701-3. doi: 10.1016/j.eururo.2025.09.4151.
 
 
- VICKERS AJ, Touijer K 
 Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic 
Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 
2025;87:619-21.
 Eur Urol. 2025 Oct 6:S0302-2838(25)04694-9. doi: 10.1016/j.eururo.2025.
 
 
- LIN PH, Burwell AD, Freedland SJ 
 Reply to Nastasiia Artamonova and Isabel Heidegger's Letter to the Editor re: 
Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in 
Prostate Cancer Prevention and Management: A Systematic Review of Prospective 
Cohort Studie
 Eur Urol. 2025 Oct 4:S0302-2838(25)04706-2. doi: 10.1016/j.eururo.2025.09.4156.
 
 
- GRAEFEN M, Falkenbach F, Maurer T, Budaus L, et al 
 Best Systemic Therapy With or Without Radical Prostatectomy in the Management of 
Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial.
 Eur Urol. 2025 Oct 3:S0302-2838(25)04687-1. doi: 10.1016/j.eururo.2025.09.4144.
 
 
 Hum Pathol
 
 
- LIN R, Li H, Baraban E, Lotan T, et al 
 Atypical intraductal proliferation (AIP) of the prostate: Findings in repeat 
biopsy or radical prostatectomy in patients who met pathologic criteria for 
active surveillance.
 Hum Pathol. 2025;160:105841.
 
 
 Int J Urol
 
 
- YASUDA Y, Wang Z, Yoshida S, Chen W, et al 
 Indirect Comparison of PROpel and TALAPRO-2 Trials Using the Shiny Method: A 
Comparative Analysis in Metastatic Castration-Resistant Prostate Cancer.
 Int J Urol. 2025 Aug 12. doi: 10.1111/iju.70194.
 
 
- ESCANDE R, Jaouen T, Gonindard-Melodelima C, Crouzet S, et al 
 External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System 
Aimed at Characterizing ISUP >/= 2 Prostate Cancers at Multiparametric MRI.
 Int J Urol. 2025;32:1440-1448.
 
 
 J Nucl Med
 
 
- CHEN DC, Buteau JP, Papa N, Akhurst T, et al 
 Prognostic Value of Initial Imaging and PSA Change with [(177)Lu]Lu-PSMA-617 
Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant 
Prostate Cancer: A ProsTIC Registry Analysis.
 J Nucl Med. 2025 Oct 9:jnumed.125.270804. doi: 10.2967/jnumed.125.270804.
 
 
- MADSEN C, Zacho HD, Fuglo D, Nielsen K, et al 
 (18)F-PSMA PET/CT Versus (18)F-NaF PET/CT for Staging and Treating Newly 
Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
 J Nucl Med. 2025 Oct 9:jnumed.125.270822. doi: 10.2967/jnumed.125.270822.
 
 
 J Urol
 
 
- KUMAR R, Lajkosz K, Hiemstra J, Finelli A, et al 
 Characterizing the Impact of Novel Patient-Centered Pathology Reports on Men 
Undergoing Prostate Biopsy: The Patient-Centered Pathology Report Randomized 
Controlled Trial.
 J Urol. 2025;214:509-520.
 
 
- EIGL BJ, Elangovan A, Ghosh S, Kim JO, et al 
 A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen 
Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The 
PRIME Study.
 J Urol. 2025;214:496-508.
 
 
- KOKOROWSKI P, Friedrich NA, Luu M, Shiang A, et al 
 Patient Participation in Consultations for Clinically Localized Prostate Cancer.
 J Urol. 2025 Oct 10:101097JU0000000000004814. doi: 10.1097/JU.0000000000004814.
 
 
 Mod Pathol
 
 
- JENNIFER NGUYEN NN, Liu K, Lajkosz K, Bernardino R, et al 
 Corrigendum to "Magnetic Resonance Imaging (MRI)-Adapted Prostate Cancer Risk 
Tool Incorporating Cribriform and Intraductal Carcinoma" (Modern Pathology 2025 
Dec;38(12):100852).
 Mod Pathol. 2025;38:100893.
 
 
 PLoS One
 
 
- MURTOLA TJ, Skantsi KM, Siltari A, Talala K, et al 
 SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer 
mortality among warfarin users in Finnish prostate cancer patients.
 PLoS One. 2025;20:e0329438.
 
 
 Prostate
 
 
- WHYNE EZ, Choi SH, Unni N, Kanjwal S, et al 
 Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer 
Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer 
Data Core.
 Prostate. 2025 Oct 8. doi: 10.1002/pros.70074.
 
 
- LIU Y, Wang H, Wang Z, Wang J, et al 
 The Infiltration of IL-18-Related Immune Cells and Their Bidirectional Regulatory 
Roles in the Pathogenesis of Prostate Cancer.
 Prostate. 2025 Oct 7. doi: 10.1002/pros.70077.
 
 
- MULCRONE J, Noakes J, Braunagel T, Hankins-Chace K, et al 
 Lessons Learned From a Mindfulness Intervention Study in Men With Newly Diagnosed 
Prostate Cancer.
 Prostate. 2025 Oct 7. doi: 10.1002/pros.70076.
 
 
- MADENDERE S, Esen B, Karaarslan UC, Muduroglu M, et al 
 Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP 
Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to 
Predict Adverse Pathology.
 Prostate. 2025 Oct 6. doi: 10.1002/pros.70073.
 
 
- TILLU N, Schussel K, P Kolanukuduru K, Choudhary M, et al 
 Diagnostic Utility of 18F-DCFPyL PSMA PET/CT-Ultrasound Fusion Biopsies Across 
the Prostate Cancer Spectrum.
 Prostate. 2025 Oct 6. doi: 10.1002/pros.70068.
 
 
- NAKAI Y, Onishi K, Asakawa I, Miyake M, et al 
 Evaluating Local Doses for Prostate Cancer Treatment Using Low-Dose-Rate 
Brachytherapy Considering Oncological Control and Toxicity.
 Prostate. 2025 Oct 6. doi: 10.1002/pros.70039.
 
 
- ROSALES RDR, Venkatesh A, Kanumuambidi JP, Ishiyama Y, et al 
 Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With 
Metastatic Prostate Cancer.
 Prostate. 2025 Oct 5. doi: 10.1002/pros.70070.
 
 
 Urology
 
 
- ORCUTT DJ, Chisholm L, Winkler E, Kaufman MR, et al 
 Patient-Centered Priorities in Prostate Cancer Survivorship Care.
 Urology. 2025 Oct 2:S0090-4295(25)00940-9. doi: 10.1016/j.urology.2025.
 
 
 
Free Medical Abstracts
 Privacy Policy
Privacy Policy
 Sponsors
Sponsors
 Share
Share
© Amedeo 1997-2016